Show
Sort by
-
- Journal Article
- A1
- open access
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC
-
- Journal Article
- A1
- open access
Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)
-
- Journal Article
- A1
- open access
11q deletion or ALK activity curbs DLG2 expression to maintain an undifferentiated state in neuroblastoma
-
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
-
Emergence of new ALK mutations at relapse of neuroblastoma
-
A multilocus technique for risk evaluation of patients with neuroblastoma
-
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification
-
Analysis of neuroblastoma tumour progression; loss of PHOX2B on 4p13 and 17q gain are early events in neuroblastoma tumourigenesis
-
Quality assessment of genetic markers used for therapy stratification
-
Report of the sixth international workshop on human chromosome 3 mapping 1995